The search for novel anticancer therapeutics with the ability to overcome multi-drug resistance (MDR) mechanisms is of high priority. A class of molecules that show potential in overcoming MDR are the N-alkylated isatins. In particular 5,7-dibromo-[ 1 1 _ T D $ D I F F ] N-alkylisatins are potent microtubule destabilizing agents that act to depolymerize microtubules, induce apoptosis and inhibit primary tumor growth in vivo. In this study we evaluated the ability of four [ 1 2 _ T D $ D I F F ] dibrominated N-alkylisatin derivatives and the parent compound, 5,7-dibromoisatin, to circumvent MDR. All of the isatin-based compounds examined retained potency against the MDR cell lines; U937VbR and MES-SA/Dx5 and displayed bioequivalent dose-dependent cytotoxicity to that of the parental control cell lines. We show that one mechanism by which the isatin-based compounds overcome MDR is by circumventing P-glycoprotein (P-gp) mediated drug efflux. Thus, as the isatin-based compounds are not susceptible to extrusion from P-gp overexpressing tumor cells, they represent a promising alternative strategy as a stand-alone or combination therapy for treating MDR cancer.
Introduction
Advances in molecular targeted anticancer agents over the past two decades have significantly improved outcomes for cancer patients. However, a major clinical obstacle to successful treatment has been the emergence of pleiotropic or multi-drug resistance (MDR), a phenomenon responsible for the decrease in efficacy of clinically used chemotherapeutics [1, 2] . MDR occurs when cancer cells become resistant to a variety of structurally and functionally unrelated anticancer agents even if the patient has not previously been exposed to that drug. An important molecular driver for MDR is overexpression of the plasma membrane glycoprotein (P-gp) [3] . P-gp is the gene product of ABCB1, a member of the ABC (ATP binding cassette) superfamily of transporter proteins, that acts as an ATP-dependent efflux pump preventing adequate intracellular accumulation of a large number of cytotoxic drugs including vinca alkaloids [4] , taxanes [5, 6] , anthracyclines [7] , epipodophyllotoxins, camptothecins [8] and some of the newer molecular targeted anticancer drugs such as imatinib [9, 10] , sorafenib [11] and everolimus [12] . Innate or acquired overexpression of P-gp is now a marker of chemoresistance and disease progression in a growing number of solid and hematologic malignancies [13, 14, 15] .
The classic pharmacological strategy to overcome P-gp mediated efflux has been the co-administration of efflux pump inhibitors and cytotoxic agents in an effort to increase the intracellular concentration of cytotoxic drugs to lethal doses.
Although several P-gp inhibitors have been evaluated in clinical trials they have all failed to date, attributable to lack of specificity, resulting in off-target organ accumulation and intolerable side effects [16] . For example, verapamil, a calcium channel blocker that also competitively inhibits P-gp transport of other substrates, is associated with cardiotoxicity at doses required to reverse MDR [17] . Cyclosporin A (CSA) causes increased nausea, vomiting, hypomagnesemia and myelosuppression [18] and second generation P-gp modulators such as valspodar, a cyclosporin D derivative that inhibits P-gp with 10-to 20-fold greater activity than CSA, significantly increases toxicity in patients with recurring and refractory multiple myeloma [19] . Given this, the search for novel therapeutics that are not substrates for drug efflux mechanisms and therefore not susceptible to extrusion from P-gp overexpressing tumor cells is of high priority and a promising alternative strategy [20] .
A group of cytotoxins that show potential in overcoming MDR are those based on the isatin (1H-indole-2,3-dione) scaffold. For example, isatin-β-thiosemicarbazones have recently been identified to selectively kill P-gp overexpressing tumor cells in vitro [21, 22] . The lead compound (NSC73306) was effective in the National Cancer Institute 60 cell line (NCI-60) drug screen with de novo or acquired P-gp induced MDR and acted indirectly to resensitize cells to previously ineffective agents [23, 24] . Other isatin derivatives that display promising anticancer activities include those derived from 5,7-dibromoisatin (1; Fig. 1 ). The synthesis and subsequent cytotoxic evaluation of a library of N-alkylisatins (mainly N-arylalkylisatins) led to the discovery that a number of these compounds possess sub-micromolar cytotoxic activity (IC 50 ) against a panel of human cancer cell lines [25, 26, 27] . One
isatin, was even shown to preferentially kill lymphoma and leukemic cancer cell lines over freshly isolated, non-transformed human peripheral blood lymphocytes [26] . Mode of action studies revealed that N-alkyl-5,7-dibromoisatins arrest cells in the G2/M phase and induce apoptosis via activation of the caspase 3/7 cascade [25, 26] .
Furthermore, tubulin binding experiments demonstrated that N-alkyl-5,7-dibromoisatins destabilize microtubule growth as evidenced by the inhibition of microtubule polymerization in the presence of structurally diverse N-alkylisatins.
Considering the role microtubule targeting chemotherapeutics play in the treatment and control of cancer, the development of novel microtubule agents that retain potency against MDR tumors is likely to have significant clinical impact in the future.
In this study we sought to evaluate the cytotoxicity of a number of cell lines and their corresponding MDR sublines (U937VbR and MES-SA/Dx5, respectively). The ability of these compounds to modulate P-gp ATPase activity was also studied to further elucidate direct drug -P-gp interactions in an effort to assess their potential as new drug candidates for treating MDR cancer.
Materials and methods

Reagents and chemicals
5,7-Dibromoisatin (1) and the N-alkylated derivatives 5, (5) were synthesized as described previously [25, 26] .
Vinblastine sulfate, colchicine, paclitaxel, doxorubicin, rhodamine-123, calcein-AM, cyclosporine A, verapamil, anti-P-gp monoclonal antibody F4 and FITC-conjugated goat anti-mouse IgG were purchased from Sigma-Aldrich (Australia). The Pgp-Glo TM assay and CellTiter 96 AQ ueous One Solution Cell
Proliferation Assay (MTS) were purchased from Promega Corporation (Australia).
Cell lines and culture conditions
The human histiocytic lymphoma (U937), uterine sarcoma parental (MES-SA) and multi-drug resistant subline (MES-SA/Dx5) were purchased from the American Type Culture Collection (ATCC, USA), distributed by Cryosite, Australia. The MES-SA/Dx5 cell line was selected by continuous in vitro exposure to doxorubicin [28] and was chosen for use in this study as its P-gp-mediated resistance by over-expression of ABCB1 is well documented [28, 29] . U937 cells were routinely cultured in RPMI-1640 medium (Invitrogen, USA) containing 5-10% (v/v) fetal calf serum (FCS, Thermo, USA) and the MES-SA cell lines were cultured in DMEM/F12 medium (Invitrogen, USA) containing 10% FCS and supplemented with 2 mM L-glutamine. Cells were maintained in culture at 37°C, 95% humidity, 5% CO 2 , in a Heracell incubator (Kendro Laboratory Products, Germany). The drug resistant U937 subline, U937VbR, was generated in-house through continuous low dose exposure (beginning with 60 nM and increasing to 120 nM) of vinblastine sulfate in culture media. The U937VbR cells underwent >20 passages in the presence of vinblastine in order to develop and maintain a resistant phenotype. Cells were harvested by centrifugation at 300 × g for 5 min and viable cells, based on trypan blue exclusion, counted using a hemocytometer. All cell lines were confirmed negative for mycoplasma contamination. of ABCB1 mRNA expression was normalised to β-actin and the relative quantification of ABCB1 was calculated according to the comparative quantification cycle (Cq) method as described by Applied Biosystems using RNA isolated from MES-SA/Dx5 cell line as the internal calibrator. PCR products were subjected to electrophoresis on a 2% agarose gel and were visualized by ethidium bromide staining to confirm size (data not shown).
Cell surface P-gp expression
Cell surface expression of P-gp was analyzed by flow cytometry. Briefly, 
Cell viability assays
In vitro cell viability assays were performed in 96-well microtiter plates as described by Vine et al. [26] using the CellTiter 96 Aqueous One Solution
Compounds 1-5 and commercial anticancer drugs were serially diluted in DMSO (final concentration 2.5%) or PBS and incubated with sensitive or drug resistant cell lines for 48 h. IC 50 values (the dose required to inhibit the metabolic activity of 50% of the cell population) were calculated from logarithmic sigmoidal dose response curves generated using GraphPad Prism v6 software (GraphPad Inc.). Data is presented as a mean ± standard deviation (SD) from ≥2 independent experiments, performed in triplicate. The resistance index (RI) was calculated to determine the degree of acquired resistance of each cell line to its selective drug and the cross resistance developed to other drugs. RI was calculated based on the following equation:
2.5. P-gp mediated efflux assays
Rhodamine 123
The presence of an active efflux pump, P-gp, was probed on U937VbR cells using the fluorescent P-gp substrate, rhodamine 123 (R123), in the absence or presence of cyclosporine A (CSA) or verapamil, specific P-gp inhibitors. Cells (5000-10,000/well) were seeded in 96-well microplates at a volume of 100 μL and incubated at 37°C for 24 h prior to addition of R123 (5 μM with ice-cold PBS (pH 7.4). Cells were lysed with 1% Triton-X, and an aliquot (80 μL) added to wells of a 96-well black plate. Fluorescence was then measured using an excitation wavelength of 485 nm, and emission wavelength of 530 nm using a FLUOstar Optima (BMG Labtech, Germany). Fluorescence measurements were normalised to protein content in each well as determined by a Lowry protein determination assay (BioRad, Australia).
Calcein-AM
Non-fluorescent calcein-AM is converted to a green-fluorescent calcein by intracellular esterases. The degree of inhibition of P-gp activity can be 
[ 1 3 _ T D $ D I F F ] 2.6. Cell morphology
The ability of the N-alkylisatins to maintain their mode of action and disrupt microtubule dynamics was determined in the MDR resistant U937VbR subline using light microscopy. Vinblastine (60 nM), colchicine (10 nM) or representative N-alkylisatins 2, 4 and 5 (2.5 μM) were incubated with U937 or U937VbR cells for 24 h and changes in cell morphology compared to control treated cells.
P-gp ATPase assay
The effect of compounds 1-5 on P-gp ATPase activity was measured using the Pgp-Glo TM assay system. Verapamil, a P-gp substrate and competitive inhibitor for other substrates, was used as a positive control. Sodium orthovanadate (Na 3 VO 4 ), a selective inhibitor of P-gp ATPase, was used to account for P-gp-independent ATP consumption in the reactions. All compounds and controls were tested at either 40 μM or 200 μM (in 1% DMSO) as per the Article No~e00060
manufacturer's protocol. Sample luminescence was recorded after 50 min incubation with the ATP detection reagent using a luminometer (POLARstar Omega, BMG Labtech, Ortenberg, Germany). Change in luminescence in relative light units (RLU; RLU Na3VO4 -RLU compound ) is inversely proportional to ATP levels, which are negatively correlated with the activity of P-gp ATPase and therefore P-gp-mediated transport.
Statistical analysis
Data is presented as a mean ± SD based on two or more independent experiments, performed in triplicate. One-way analysis of variance (ANOVA) using a Dunnett's multiple comparisons post-test or t-tests were used to determine the significance among groups (GraphPad Prism 6.01). P-values < 0.05 were considered significant.
Results
U937VbR and MES-SA/Dx5 overexpress ABCB1 mRNA and its protein product P-gp
In order to ascertain if P-gp mediated efflux contributes to the mechanism of resistance of our newly generated U937VbR cell line to the commercial anticancer drugs vinblastine, colchicine, paclitaxel and doxorubicin, as well as compounds 1-5, we probed for expression of the ABCB1 gene, coding for P-gp, by RT-qPCR. The U937VbR cells exhibited a 765-fold increase in ABCB1 mRNA transcript levels compared to the parental U937 cells ( Fig. 2A) , which were similar to that expressed in the control MES-SA/Dx5 multi-drug resistant cell line, previously reported to highly express P-gp [29] . Increased ABCB1 mRNA expression was associated with a 3-4-fold increase in cell surface expression of P-gp on both resistant cell lines compared to their parental controls (Fig. 2B) as determined by immunofluorescence staining and flow cytometry. This result was also confirmed by assessing the uptake and retention of the fluorescent P-gp substrate R123 ( Supplementary Information, Fig. S1 ). (Fig. 3A & B) . The U937VbR subline exhibited the greatest resistance to vinblastine and colchicine with a 4.2 ± 0.3 and 4.9 ± 0.5-fold decrease in drug sensitivity, respectively. Conversely the MES-SA/Dx5 subline displayed the greatest resistance to doxorubicin and paclitaxel with a 5.0 ± 0.6 and 4.7 ± 0.3-fold decrease in drug sensitivity, respectively after 48 h.
Comparison of the dose response curves for the isatin derivatives (1-5) against the MDR cell lines U937VbR and MES-SA/Dx5 found them to be bioequivalent to their respective chemosensitive cell lines at both 24 h ( Fig. S2; Supplementary Information) and 48 h (Fig. 4 and Fig. 5 ). This was irrespective (Table 1) .
Cell morphology
We have previously reported that lymphocytic cell lines display characteristic changes and elongated cell morphology after treatment with N-alkylisatins targeting tubulin polymerization [25, 26, 30] . We therefore monitored the morphology of resistant and parental U937 cell lines after treatment with the commercial microtubule targeting drugs, vinblastine and colchicine and [ (5) (5) 
( F i g . _ 4 ) T D $ F I G ]
[ ( F i g . _ 6 ) T D $ F I G ] the rate of calcein AM efflux, leading to increased intracellular calcein AM, which is then hydrolyzed by intracellular esterases, converting it to the fluorescent product calcein. Free calcein is hydrophilic and thus retained inside the cells. After 40 min the proportion of calcein positive cells was 1.5 times greater for cells treated with the P-gp inhibitor CSA than for cells treated with the vehicle control (P = 0.0014; Fig 7A) . No significant increase in intracellular accumulation of calcein was seen after incubation with compounds 1-5 compared to the vehicle control, indicating that isatins do not inhibit P-gp.
P-gp ATPase assay
In order to further confirm that compounds 1-5 do not directly interact with P-gp, we measured the change in luminescence associated with P-gp ATPase hydrolysis. Compounds that do not directly interact with P-gp have no effect on basal ATPase activity; compounds that are substrates for transport by P-gp stimulate basal ATPase activity while inhibitors decrease basal ATPase activity. Verapamil is a substrate for P-gp transport and showed a significant increase in the change in luminescence (RLU Na3VO4 -RLU verapamil ) at 40 μM and
0.05 and P < 0.01, respectively) compared to basal activity (RLU Na3VO4 -RLU untreated ), which represents verapamil-stimulated P-gp ATPase activity (Fig. 7) . Compounds 1-5 did not show a significant change in luminescence compared to basal activity; therefore, N-alkylisatins do not interact with P-gp.
Discussion
MDR has become a major barrier to the clinical efficacy of a wide range of chemotherapeutic drugs, prompting the development of new strategies in cancer treatment [31, 32, 33, 34] . colchicine and anthracyclines [35, 36, 37] . The mechanism of resistance is primarily due to over-expression of the efflux pump protein, P-gp [1, 38] .
We found the most effective method for inducing vinblastine resistance in the U937 cell line was through continuous low dose exposure to 120 nM vinblastine, excluding a recovery period in drug-free media. A resistance index (RI) of 75 was observed for vinblastine and cross-resistance to structurally unrelated chemotherapeutics such as colchicine, paclitaxel and doxorubicin was Data are presented as the mean ± SD (n = 3). **P < 0.01; *P < 0.05; ns = not significant.
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clearly demonstrated ( Fig. 3 ; Table 1 ). Marked upregulation of the ABCB1 gene and decreased uptake and retention of the P-gp substrate R123 was observed in the U937VbR cell line suggesting that P-gp mediated drug efflux plays a role in the chemoresistance profile observed in this new subline. Other mechanisms of resistance to microtubule-binding agents such as the Vinca alkaloids and taxanes include alterations to their microtubule targets. Mechanisms such as mutations in the binding motifs in α-or β-tubulin, or upregulation of alternative tubulin isotypes such as βIII tubulin have been shown to be important in driving paclitaxel and vincristine resistance in non-small-cell lung cancer however reasons for this are still poorly understood [39] . Cross-resistance of such mechanisms, however, appear to be limited to tubulin-binding agents only, suggesting that they are not the determinant of the MDR phenotype observed in response to continuous exposure to vinblastine in this study. This is supported by our cell morphology studies (Fig. 6 ) which indicates that there has been no change in the intracellular microtubule target of the isatins under the selection pressure of the microtubule disrupting agent vinblastine. Further, the breast cancer resistance protein (BCRP) [40] , another ATP-binding cassette transporter capable of inducing drug resistance, does not confer resistance to the Vinca alkaloids, epipodophyllotoxins, paclitaxel, or cisplatin [41] suggesting that it is unlikely to be contributing to the MDR phenotype observed in our MDR subline. While our data is consistent with overexpression of ABCB1 as the major efflux mechanism responsible for the resistant phenotype observed in the U937VbR cell line in this study, the expression of other efflux pumps such as multidrug resistance associated-protein 1 (MRP1) should also be profiled to fully complete characterization.
Four structurally diverse N-alkylisatin analogues (2-5) and the parent dibromoisatin molecule (1) were chosen for use in this study due to the N-alkylisatins' relatively high potency and synthetic availability. Furthermore, while P-gp and MRP are capable of extruding a wide variety of anticancer compounds, they can't remove them all, with structures containing the indole core featuring heavily in a growing number of anticancer and antibacterial compounds that are not substrates of, or can reverse drug efflux mechanisms [21, 42, 43] . The cytotoxic effect of compounds 1-5 was therefore evaluated in our in vitro MDR model system to determine their potential susceptibility to P-gp-mediated efflux. Two different parental cell lines were used; one derived from human histiocytic lymphoma and the other from human uterine sarcoma, as MDR screening is most often performed in model systems which employ cell lines derived from hematological malignancies while the use of cell lines derived from solid tumors is usually less popular [29] . The IC 50 values obtained for all 5 isatin-based compounds against the U937VbR and MES-SA/Dx5 MDR cell lines. Further, the dose response profiles were virtually superimposable and not statistically different by 2 way ANOVA, which was in contrast to the dose response profiles of the commercial anticancer agents, suggesting that this class of molecule is not susceptible to P-gp-mediated efflux over concentrations ranging from 100 nM-100 μM. Importantly, the growth properties of the resistant cell lines were identical to that of the parental cell lines (Supplementary Information Fig. S3 ) suggesting that differences in cell population doubling time (rate of mitosis) did not impact on our findings.
Our results corroborate those reported by Hall et al. who describe isatin-β-thiosemicarbazones to be neither substrates nor inhibitors of P-gp, but which also act to reduce P-gp expression [21, 22] . While the effect of isatins 1-5 on the expression of P-gp was not interrogated in this study, experiments are underway to investigate the effect on ABCB1 expression in U937 and MES-SA cell lines after long-term, continuous culture with 5,7-dibromo-N-(phydroxymethylbenzyl) isatin (2) . Preliminary findings suggest continuous exposure to increasing concentrations of compound 2 over a period of 4 months does not result in significant upregulation of ABCB1 and cells maintain drug sensitivity (Supplementary Information Fig. S4 ).
Research within our laboratory has demonstrated that N-benzylation of 5,7-dibromoisatin substantially increases cytotoxic activity in vitro by up to two orders of magnitude against a range of human cancer cell lines [25, 26] . Using pharmacophores, Hall et al. identified the aromatic/hydrophobic groups at the N4 position of the thiosemicarbazone, as well as the isatin moiety, to be important features for the maintenance of MDR-selective activity [21, 22] . In this study, structure activity relationship experiments found that alkylation at the N1 position increased cytotoxic activity as reported [25, 26] , but had no effect on MDR-selective activity, confirming reliance on the isatin core. While the mechanisms by which the isatins overcome MDR have not yet been elucidated, we can hypothesize that may they include poor P-gp substrate affinity, ability to alter the biophysical properties of the plasma membrane or enter the cell via alternative drug uptake mechanisms.
Conclusions
The emergence of resistance to clinical cancer treatments poses a significant problem in the management and treatment of cancer. While combination therapies are showing promise, there is still a need to develop more efficacious therapeutics that are able to overcome resistance mechanisms employed by tumor cells. The potential novel interaction of the N-alkylisatins with tubulin, together with their high potency in vitro and ability to inhibit tumor growth in vivo, point to the importance of further investigations into these compounds.
